University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

The administration is reviewing a Centers for Medicare and Medicaid Services rule that would expand coverage to Medicare and Medicaid recipients ...

Join Drs Steven Feldman and Robert Kushner as they discuss the role of dermatologists in treating obesity in conjunction with psoriasis.

No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Fortunately, with President Trump’s leadership on the issue, he can turn the tide in the quest to end obesity. There’s a ...

ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates ...

The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

I’ve introduced legislation in Florida to expand options for obesity treatment, including public health insurance coverage. | ...

The federal government spends over $90 billion annually across Medicare and Medicaid treating obesity and its comorbidities. In comparison, the proposed CMS rule is estimated to cost approximately ...